Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic... To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pubmed

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Download PDF

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.


Abstract

To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies.

Loading next page...
 
/lp/pubmed/phase-i-trial-of-the-proteasome-inhibitor-ps-341-in-patients-with-uaBMMDAIgi

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0732-183X
DOI
10.1200/JCO.2002.01.133
pmid
12431963

Abstract

To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies.

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology – Pubmed

Published: Feb 21, 2003

There are no references for this article.